The US government has provided almost $24 million in funding to Locus Biosciences to support a mid-stage trial of LBP-EC01, a CRISPR-engineered bacteriophage therapy in development for resistant ...
A deficiency of the enzyme iduronate-2-sulfatase (IDS) is the cause of Hunter syndrome (mucopolysaccharidosis type II). Here, we report a study of the human IDS locus at Xq28. An unexpected finding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results